Two Democratic lawmakers introduced a bill to reverse the Trump administration’s decision to end a Medicare prescription drug subsidy program and extend it through 2029. Representatives Kathy Castor of Florida and Terri Sewell of Alabama have presented the Affordable Premiums for Seniors Act. This legislation aims to sustain the Medicare Part D Premium Stabilization Demonstration beyond 2026.
Recently, the Trump administration stated that the Centers for Medicare & Medicaid Services (CMS) plans to terminate the program by the end of next year. Kathy Castor expressed her concerns: “Every trip to the grocery store and every monthly bill is increasingly painful for my older neighbors. The added strain of higher prescription drug costs is the last thing they need, so I will fight to reverse a recent HHS scheme to increase Medicare prescription drug costs for seniors and people with disabilities.” Castor emphasized that the Affordable Premiums for Seniors Act seeks to mitigate this scheme, reduce premiums, and provide greater predictability in healthcare costs.
Importance of the Legislation
Nearly 25 million people were enrolled in standalone Medicare Part D prescription drug plans in 2026, based on KFF data. Without the stabilization program, some beneficiaries may face significant premium hikes in 2027. Retirees living on fixed incomes are already struggling with rising housing and healthcare expenses. Lawmakers are advocating for the subsidy to keep drug coverage affordable, while the Trump administration insists that additional subsidies are no longer needed.
Key Details of the Bill
The Affordable Premiums for Seniors Act aims to:
- Extend the Medicare Part D Premium Stabilization Demonstration through 2029.
- Preserve federal premium assistance for standalone Medicare Part D plans.
- Maintain lower monthly prescription drug premiums for beneficiaries.
- Reverse the Trump administration’s decision to end the program after 2026.
Kevin Thompson, CEO of 9i Capital Group, stated, “Lowering premiums for people at the lower end of the income spectrum, particularly those who rely heavily on prescription drugs, is a definite benefit for beneficiaries living on fixed incomes.” However, he also pointed out that subsidizing insurers instead of addressing underlying drug costs is debated.
The Medicare Payment Advisory Commission (MedPAC) noted that the subsidy saved seniors an average of $312 in 2026. Sewell stated that ending the Part D Premium Stabilization Program could lead to higher premiums and financial strain for seniors. She emphasized that the Affordable Premiums for Seniors Act would secure stability and certainty for Medicare beneficiaries.
CMS and the Trump Administration’s Stance
CMS announced the end of the demonstration program after evaluating 2027 plan bids. Mehmet Oz of CMS defended the decision, stating that additional subsidies act as unnecessary bailouts for insurers. He mentioned, “We are stabilizing the market so this bailout is no longer needed.” The anticipated national base beneficiary premium for Medicare Part D in 2027 will be $41.33, with final figures expected later this year.
The stance of CMS suggests that the subsidy was temporary and claims that continued subsidization transfers costs back to taxpayers. The key issue moving forward is whether the market is prepared to operate without this support.
Future Prospects
The future of the bill remains uncertain in a Republican-controlled Congress and requires approval from both chambers to reach the President. As Medicare beneficiaries anticipate the final 2027 Part D premium announcements, it will offer a clearer indication of potential cost increases without the stabilization program. Kevin Thompson noted, “Democrats simply don’t have the votes, and Republicans currently hold congressional power. Without bipartisan support, extending the subsidy will be difficult.”